3081 Molecular Tumor Board (MTB) in non-small cell lung cancers (NSCLC) to optimize targeted therapies: 4 years' experience at Gustave Roussy

2015 ◽  
Vol 51 ◽  
pp. S624 ◽  
Author(s):  
D. Planchard ◽  
L. Faivre ◽  
I. Sullivan ◽  
V. Kahn-charpy ◽  
L. Lacroix ◽  
...  
Keyword(s):  
Targeted Therapies ◽  
Small Cell ◽  
Tumor Board ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Molecular Tumor Board

scholarly journals Making the Most of Complexity to Create Opportunities: Comprehensive Genomic Profiling and Molecular Tumor Board for Patients with Non-Small Cell Lung Cancer (NSCLC)

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 609
Author(s):  
Caterina Fumagalli ◽  
Elena Guerini-Rocco ◽  
Massimo Barberis
Keyword(s):  
Lung Cancer ◽  
Small Cell ◽  
Tumor Board ◽  
Genomic Profiling ◽  
Small Cell Lung ◽  
Molecular Alterations ◽  
Comprehensive Genomic Profiling ◽  
Molecular Tumor Board ◽  
Personalized Cancer Therapy ◽  
Personalized Cancer

Personalized cancer therapy matches the plan of treatment with specific molecular alterations [...]

scholarly journals Molecular tumor board: Case 1-Interplay of EGFR, MET and PD-L1 in non-small cell lung carcinoma

2019 ◽  
Vol 2 (2) ◽  
pp. 228
Author(s):  
Anuradha Chougule ◽  
Akhil Kapoor ◽  
Vanita Noronha ◽  
VijayM Patil ◽  
Nandini Menon ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Tumor Board ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Molecular Tumor Board

scholarly journals Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer

2020 ◽  
Vol 13 (11) ◽  
pp. 374
Author(s):  
Lisa Mustachio ◽  
Jason Roszik
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Targeted Therapies ◽  
Treatment Strategies ◽  
The United States ◽  
Current Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers

Lung cancers contribute to the greatest number of cancer-related deaths worldwide and still pose challenges in response to current treatment strategies. Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers diagnosed in the United States and novel therapeutics are needed for the treatment of this disease. First and second generation targeted therapies against specific mutated or rearranged oncogenes in NSCLCs show anti-tumor activity and also increase survival. However, many NSCLC patients eventually develop resistance to these therapies or do not properly respond if they have central nervous system metastases. Thus, this review summarizes recent developments and findings related to the generation of novel targeted therapies recently or currently being developed to tackle hurdles that prior therapies were not able to overcome.

scholarly journals Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors

2015 ◽  
Vol 11 (5) ◽  
pp. 865-878 ◽  
Author(s):  
Shanthi Kanthala ◽  
Sandeep Pallerla ◽  
Seetharama Jois
Keyword(s):  
Targeted Therapies ◽  
Small Cell ◽  
Egf Receptors ◽  
Small Cell Lung ◽  
Lung Cancers
Sign in / Sign up

Export Citation Format

Share Document